Formation Bio described an AI‑native model that prioritizes clinical development workflows to speed and derisk drug programs; CTO Dan Neil outlined the hub‑and‑spoke asset structure and platform‑driven execution that helped the company raise more than $600m. Formation argues clinical execution, not discovery, offers immediate AI leverage in speeding trials and reducing cost. Insilico Medicine appointed Dr. Halle Zhang as VP of Clinical Development for Oncology, signaling continued growth among AI‑driven biotech firms recruiting clinical development talent to bridge computational discovery and trials. Zhang joins Insilico’s Cambridge team to lead oncology clinical programs. Together, the announcements reflect industry moves to integrate generative AI and machine learning across trial design, patient selection, and development operations—shifting hiring toward clinical and regulatory expertise to translate algorithmic leads into human data.